MCID: SCN001
MIFTS: 40

Secondary Hyperparathyroidism of Renal Origin

Categories: Endocrine diseases, Nephrological diseases

Aliases & Classifications for Secondary Hyperparathyroidism of Renal Origin

MalaCards integrated aliases for Secondary Hyperparathyroidism of Renal Origin:

Name: Secondary Hyperparathyroidism of Renal Origin 12
Secondary Hyperparathyroidism 12 36 14
Hyperparathyroidism, Secondary 41 69
Hyperparathyroidism Due to Renal Insufficiency 12
Secondary Hyperparathyroidism Nos 12
Hyperparathyroidism Secondary 51

Classifications:



External Ids:

Disease Ontology 12 DOID:12465 DOID:12466
ICD10 32 N25.81 E21.1
ICD9CM 34 588.81
MeSH 41 D006962
NCIt 46 C113335
KEGG 36 H01669

Summaries for Secondary Hyperparathyroidism of Renal Origin

MalaCards based summary : Secondary Hyperparathyroidism of Renal Origin, also known as secondary hyperparathyroidism, is related to hyperparathyroidism and non-renal secondary hyperparathyroidism. An important gene associated with Secondary Hyperparathyroidism of Renal Origin is PTH (Parathyroid Hormone), and among its related pathways/superpathways are Ca, cAMP and Lipid Signaling and Development_Hedgehog and PTH signaling pathways in bone and cartilage development. The drugs Sevelamer and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include bone, and related phenotypes are endocrine/exocrine gland and hematopoietic system

Related Diseases for Secondary Hyperparathyroidism of Renal Origin

Diseases related to Secondary Hyperparathyroidism of Renal Origin via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Related Disease Score Top Affiliating Genes
1 hyperparathyroidism 26.0 ACP5 BGLAP CALCA CASR CYP27B1 EPO
2 non-renal secondary hyperparathyroidism 12.1
3 hypocalciuric hypercalcemia, familial, type ii 10.5 CASR PTH
4 familial hypocalciuric hypercalcemia 10.4 CASR PTH
5 oncogenic osteomalacia 10.4 FGF23 PTH
6 hypercalciuria, absorptive, 2 10.4 CASR VDR
7 axial osteomalacia 10.4 BGLAP PTH
8 extraskeletal chondroma 10.4 BGLAP PTH
9 pulmonary alveolar microlithiasis 10.4 FGF23 PTH
10 spondylosis 10.4 PTH VDR
11 pseudohypoparathyroidism, type ib 10.3 BGLAP PTH
12 xanthinuria, type i 10.3 CASR VDR
13 vitamin d-dependent rickets, type 2a 10.3 CYP27B1 VDR
14 multicentric carpotarsal osteolysis syndrome 10.3 BGLAP TNFRSF11B
15 nephrolithiasis, calcium oxalate 10.3 CASR VDR
16 fanconi syndrome 10.2 ALB PTH
17 sialolithiasis 10.2 ALB CASR
18 chondrocalcinosis 10.2 CASR TNFRSF11B
19 impaired renal function disease 10.2 BGLAP FGF23 PTH
20 idiopathic hypercalciuria 10.2 BGLAP CASR VDR
21 hypophosphatemia 10.2 BGLAP FGF23 PTH
22 camurati-engelmann disease 10.2 ACP5 BGLAP
23 periapical periodontitis 10.1 ACP5 TNFRSF11B
24 osteoporosis, juvenile 10.1 BGLAP CALCA
25 pseudohypoparathyroidism 10.1 BGLAP PTH
26 cloacogenic carcinoma 10.1 CALCA PTH
27 tooth resorption 10.1 ACP5 TNFRSF11B
28 nontoxic goiter 10.1 BGLAP CALCA
29 paget disease of bone 5, juvenile-onset 10.1 CALCA TNFRSF11B
30 autonomic nervous system disease 10.1 ALB CALCA
31 hypervitaminosis d 10.1 CYP27B1 FGF23 PTH
32 uremic neuropathy 10.1 EPO PTH
33 primary biliary cirrhosis 10.1 ALB BGLAP VDR
34 hypophosphatemic rickets with hypercalciuria, hereditary 10.1 CYP27B1 FGF23 PTH
35 cohen-gibson syndrome 10.1 BGLAP FGF23 TNFRSF11B
36 mccune-albright syndrome 10.1 BGLAP FGF23
37 hypophosphatemic rickets, x-linked recessive 10.0 CYP27B1 FGF23 VDR
38 parathyroid carcinoma 10.0 CALCA CASR PTH
39 multiple endocrine neoplasia, type iia 10.0 CALCA PTH
40 hyperphosphatemia 10.0 CASR FGF23 PTH VDR
41 bone giant cell tumor 10.0 ACP5 CALCA
42 hypocalcemia, autosomal dominant 1 10.0 CALCA CASR VDR
43 metaphyseal chondrodysplasia, jansen type 10.0 CALCA FGF23 PTH
44 root resorption 10.0 CALCA TNFRSF11B
45 hypophosphatasia, adult 10.0 BGLAP CALCA PTH
46 splenic disease 10.0 ALB EPO
47 hypoparathyroidism 10.0 BGLAP CASR FGF23 PTH
48 degenerative disc disease 10.0 CALCA VDR
49 diabetes mellitus, insulin-dependent 10.0 ALB BGLAP VDR
50 fetal erythroblastosis 9.9 ALB EPO

Graphical network of the top 20 diseases related to Secondary Hyperparathyroidism of Renal Origin:



Diseases related to Secondary Hyperparathyroidism of Renal Origin

Symptoms & Phenotypes for Secondary Hyperparathyroidism of Renal Origin

MGI Mouse Phenotypes related to Secondary Hyperparathyroidism of Renal Origin:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.8 FGF23 PTH ALB VDR CASR CYP27B1
2 hematopoietic system MP:0005397 9.8 FGF23 PTH TNFRSF11B VDR CASR CYP27B1
3 limbs/digits/tail MP:0005371 9.63 PTH TNFRSF11B VDR CYP27B1 EPO FGF23
4 renal/urinary system MP:0005367 9.35 FGF23 VDR ALB CASR CYP27B1
5 skeleton MP:0005390 9.17 PTH TNFRSF11B VDR CASR CYP27B1 EPO

Drugs & Therapeutics for Secondary Hyperparathyroidism of Renal Origin

Drugs for Secondary Hyperparathyroidism of Renal Origin (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevelamer Approved Phase 4,Phase 3,Phase 2,Not Applicable 52757-95-6, 152751-57-0 3085017
2
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
3
Ethanol Approved Phase 4 64-17-5 702
4
Alendronate Approved Phase 4,Phase 2 121268-17-5, 66376-36-1 2088
5
Angiotensin II Approved, Investigational Phase 4,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
6
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 471-34-1
7
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2, 11096-26-7
8
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
9
Iron Approved Phase 4 7439-89-6 23925
10
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
11 Racepinephrine Approved Phase 4 329-65-7
12
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1406-16-2
13
Calcitriol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 32222-06-3 5280453 134070
14 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable
15
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 67-97-0 10883523 5280795 6221
16
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-14-6 5280793
17
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
18
Alfacalcidol Approved, Nutraceutical Phase 4,Not Applicable 41294-56-8 5282181
19
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
20
Nicotinamide Approved, Investigational, Nutraceutical Phase 4 98-92-0 936
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
22 1 alpha-hydroxyergocalciferol Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Cinacalcet Hydrochloride Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Calcimimetic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Calcifediol Phase 4,Phase 3,Not Applicable 19356-17-3
37
s 1 (combination) Phase 4,Phase 2
38 Retinol palmitate Phase 4
39 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Hematinics Phase 4
41 Dihydroxycholecalciferols Phase 4,Phase 2
42 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 2
43 Angiotensin Receptor Antagonists Phase 4,Phase 2
44 Angiotensinogen Phase 4,Phase 2
45 Antacids Phase 4,Phase 3,Phase 2,Not Applicable
46 Hydroxycholecalciferols Phase 4,Phase 3,Not Applicable
47 Epoetin alfa Phase 4 113427-24-0
48 Immunoglobulin A Phase 4,Phase 3
49 Immunoglobulins Phase 4,Phase 3
50 Antihypertensive Agents Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 196)

# Name Status NCT ID Phase Drugs
1 Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4 Combination Cinacalcet with Vitamin D analogue
2 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity Unknown status NCT00288873 Phase 4 Ergocalciferol;Cholecalciferol
3 How Bone is Made in Children Receiving Dialysis Unknown status NCT01799317 Phase 4 Vitamin D2
4 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
5 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
6 Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation Completed NCT01178450 Phase 4 Cinacalcet
7 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4 alfacalcidol and calcitriol
8 ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism Completed NCT00135304 Phase 4 Sensipar®;Vitamin D
9 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Completed NCT00823303 Phase 4 Paricalcitol;Calcitriol
10 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4 Paricalcitol injection;Paricalcitol capsules
11 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed NCT01939977 Phase 4 Paricalcitol;Calcifediol
12 START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Completed NCT00132431 Phase 4 Sensipar
13 Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism Completed NCT00123461 Phase 4 Hectorol (doxercalciferol capsules), 0.5mcg
14 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4 Traditional Vitamin D Therapy;Cinacalcet
15 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4 Zemplar (paricalcitol)
16 20070360 Incident Dialysis Completed NCT00803712 Phase 4 Cinacalcet;Vitamin D
17 Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level Completed NCT01101113 Phase 4 cinacalcet;control
18 A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection Completed NCT00463021 Phase 4 Hectorol (doxercalciferol capsules);Zemplar (paricalcitol injection)
19 Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism Completed NCT01143987 Phase 4 Cinacalcet
20 A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis Completed NCT00418600 Phase 4 Hectorol® (doxercalciferol capsules);doxercalciferol capsules, Hectorol®;doxercalciferol capsules, Hectorol® capsules
21 Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients Completed NCT00958451 Phase 4 Paricalcitol;Ergocalciferol
22 Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Completed NCT00073710 Phase 4 Zemplar;Calcijex
23 Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D Completed NCT00977080 Phase 4 Paricalcitol;Cinacalcet
24 Treatment Adhesion in Dialysis Patients Treated With Cinacalcet Completed NCT01573520 Phase 4
25 A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) Completed NCT00431496 Phase 4 Cinacalcet
26 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients Completed NCT01506947 Phase 4 Paricalcitol;Darbepoetin alfa
27 A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis Completed NCT00454350 Phase 4 Hectorol (doxercalciferol injection);Zemplar (Paricalcitol injection)
28 Trial to Optimize Mineral Outcomes in Dialysis Patients Completed NCT01100723 Phase 4
29 Vitamin D and Coronary Calcification Study Completed NCT00752102 Phase 4 Calcitriol (Rocaltrol®);Paricalcitol
30 A Research Study for Patients With End-Stage Renal Disease (ESRD) Completed NCT00110890 Phase 4 cinacalcet
31 Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis Completed NCT00053547 Phase 4 paricalcitol injection
32 Paricalcitol Effect on Anemia in CKD Completed NCT01768351 Phase 4 Paricalcitol;Calcitriol
33 A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease Completed NCT00257920 Phase 4 Zemplar® injection;Hectorol® injection
34 Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density Completed NCT01025128 Phase 4 25 OH vitamin D
35 Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol Completed NCT01748396 Phase 4 Calcitriol;Calcium Carbonate
36 Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy Completed NCT00319761 Phase 4 Calcitriol
37 Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria. Completed NCT02238418 Phase 4 Cholecalciferol vial (100 000 UI)
38 Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease Completed NCT00395382 Phase 4 Alendronate;Placebo
39 Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder Completed NCT01633853 Phase 4 Vitamin D2;1,25(OH)2 Vit D3
40 How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Completed NCT00528788 Phase 4 doxercalciferol
41 ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Completed NCT00379899 Phase 4 cinacalcet
42 Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients Recruiting NCT03182699 Phase 4
43 Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT Recruiting NCT03123406 Phase 4 Cinacalcet HCl
44 Physiologic Interactions Between the Adrenal- and the Parathyroid Glands Recruiting NCT02572960 Phase 4 Valsartan;Placebo Valsartan
45 Paricalcitol Improves Anemia of Inflammation Recruiting NCT02876211 Phase 4 Paricalcitol;Epoetin beta;Placebo
46 Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease Recruiting NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
47 Intravenous Paricalcitol in Chronic Hemodialysis Patients Active, not recruiting NCT03023748 Phase 4 Intravenous Paricalcitol
48 The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis Not yet recruiting NCT03163576 Phase 4 Niacin;Phosphate Binder
49 Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects Terminated NCT00664430 Phase 4 Calcitriol;Paricalcitol
50 Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis Terminated NCT00446329 Phase 4 cinacalcet

Search NIH Clinical Center for Secondary Hyperparathyroidism of Renal Origin

Cochrane evidence based reviews: hyperparathyroidism, secondary

Genetic Tests for Secondary Hyperparathyroidism of Renal Origin

Anatomical Context for Secondary Hyperparathyroidism of Renal Origin

MalaCards organs/tissues related to Secondary Hyperparathyroidism of Renal Origin:

38
Bone

Publications for Secondary Hyperparathyroidism of Renal Origin

Articles related to Secondary Hyperparathyroidism of Renal Origin:

(show top 50) (show all 402)
# Title Authors Year
1
Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients. ( 29439405 )
2018
2
Periosteal chondroma of the cuboid with secondary aneurysmal bone cyst in a setting of secondary hyperparathyroidism. ( 29413778 )
2018
3
Cortical and trabecular bone are equally affected in rats with renal failure and secondary hyperparathyroidism. ( 29394885 )
2018
4
Influence of Parathyroidectomy on Bone Metabolism and Bone Pain in Patients with Secondary Hyperparathyroidism. ( 29393259 )
2018
5
Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. ( 29423207 )
2018
6
Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis. ( 29449603 )
2018
7
Management of secondary hyperparathyroidism: how and why? ( 28044233 )
2017
8
A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. ( 28057872 )
2017
9
Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. ( 28063122 )
2017
10
Brown tumor: clinical findings of secondary hyperparathyroidism in patients with renal osteodystrophy. ( 28253186 )
2017
11
Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1I+,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ( 28905271 )
2017
12
Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. ( 28073343 )
2017
13
Acute thyroiditis: An under-recognized complication of parathyroidectomy in end-stage renal failure patients with secondary hyperparathyroidism. ( 28621009 )
2017
14
Ultrasound-based scores as predictors for nodular hyperplasia in patients with secondary hyperparathyroidism: a prospective validation study. ( 28054194 )
2017
15
Hyperparathyroidism caused by distant pulmonary lesions and parathyromatosis after ethanol injection/parathyroidectomy for secondary hyperparathyroidism. ( 28078796 )
2017
16
High Incidence of Secondary Hyperparathyroidism in Bariatric Patients: Comparing Different Procedures. ( 28921422 )
2017
17
Pin1 and secondary hyperparathyroidism of chronic kidney disease: gene polymorphisms and protein levels. ( 27876426 )
2017
18
Evaluation of the different surgical parathyroidectomieson secondary hyperparathyroidism in uremia patients. ( 29205012 )
2017
19
Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia. ( 29247451 )
2017
20
Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitaminA D in Austria and Switzerland - the observational TRANSIT Study. ( 28091752 )
2017
21
Associations of the calcium-sensing receptor gene CASR rs7652589 SNP with nephrolithiasis and secondary hyperparathyroidism in haemodialysis patients. ( 27739473 )
2016
22
Cinacalcet versus Parathyroidectomy in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation. ( 27658167 )
2016
23
Efficacy and safety of ultrasound-guided radiofrequency ablation of hyperplastic parathyroid gland for secondary hyperparathyroidism associated with chronic kidney disease. ( 28032671 )
2016
24
Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. ( 27639083 )
2016
25
Literature review in the treatment of calciphylaxis: A case with uncontrolled and severe secondary hyperparathyroidism. ( 26958335 )
2016
26
Brown tumor of secondary hyperparathyroidism: surgical approach and clinical outcome. ( 27640197 )
2016
27
Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis. ( 27198474 )
2016
28
Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. ( 27933339 )
2016
29
Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. ( 27988213 )
2016
30
The relationship between total mass and blood supply of parathyroid glands and their secretion of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. ( 26997379 )
2016
31
Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease. ( 27142279 )
2016
32
Warfarin skin necrosis mimicking calciphylaxis in a patient with secondary hyperparathyroidism undergoing peritoneal dialysis. ( 27069859 )
2016
33
Micro-RNAs in the parathyroid: a new portal in understanding secondary hyperparathyroidism. ( 27138227 )
2016
34
Impact of Phosphorus Restriction and Vitamin D-Substitution on Secondary Hyperparathyroidism in a Proteinuric Mouse Model. ( 25871296 )
2015
35
Gene mutations in chronic kidney disease patients with secondary hyperparathyroidism and Sagliker syndrome. ( 25701941 )
2015
36
Application of total parathyroidectomy with auto-transplantation for uremia secondary hyperparathyroidism treatment. ( 26379922 )
2015
37
SECONDARY HYPERPARATHYROIDISM AFTER BARIATRIC SURGERY: TREATMENT IS WITH CALCIUM CARBONATE OR CALCIUM CITRATE? ( 26537273 )
2015
38
Expanding the net: The re-evaluation of the multidimensional nomogram calculating the upper limit of normal PTH (maxPTH) in the setting of secondary hyperparathyroidism andA the development of the MultIdimensional Predictive hyperparaTHyroid model (Mi-PTH). ( 26531237 )
2015
39
Sagliker syndrome in patients with secondary hyperparathyroidism and chronic renal failure: Case report. ( 25661637 )
2015
40
Surgical Attitude in Patients with Secondary Hyperparathyroidism Undergoing Dialysis. ( 26531784 )
2015
41
Short-term efficacy of surgical treatment of secondary hyperparathyroidism. ( 26531277 )
2015
42
NaF18-PET/CT Imaging of Secondary Hyperparathyroidism. ( 26550056 )
2015
43
Predicting postoperative total calcium requirements after parathyroidectomy in secondary hyperparathyroidism. ( 26552461 )
2015
44
A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). ( 25904755 )
2015
45
Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. ( 25873267 )
2015
46
Facial disfigurement due to osteitis fibrosa cystica or brown tumor from secondary hyperparathyroidism in patients on dialysis: A systematic review and an illustrative case report. ( 25828738 )
2015
47
Short And Long-Term Economic Impact of Secondary Hyperparathyroidism Treatment in Chronic Kidney Disease in Carlos Andrade Marin Hospital (Ecuador). ( 26534522 )
2015
48
AN OVERVIEW OF NURSES' MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM: HOW IS EUROPE DOING? ( 25899821 )
2015
49
Effect of secondary hyperparathyroidism serum on endothelial cells and intervention with Klotho. ( 25873020 )
2015
50
Location Frequency of Missed Parathyroid Glands After Parathyroidectomy in Patients with Persistent or Recurrent Secondary Hyperparathyroidism. ( 26563219 )
2015

Variations for Secondary Hyperparathyroidism of Renal Origin

Expression for Secondary Hyperparathyroidism of Renal Origin

Search GEO for disease gene expression data for Secondary Hyperparathyroidism of Renal Origin.

Pathways for Secondary Hyperparathyroidism of Renal Origin

GO Terms for Secondary Hyperparathyroidism of Renal Origin

Cellular components related to Secondary Hyperparathyroidism of Renal Origin according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 ALB BGLAP CALCA EPO FGF23 PTH
2 extracellular space GO:0005615 9.17 ALB BGLAP CALCA EPO FGF23 PTH

Biological processes related to Secondary Hyperparathyroidism of Renal Origin according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.85 CALCA EPO FGF23 PTH TNFRSF11B
2 cellular protein metabolic process GO:0044267 9.8 ALB CALCA FGF23
3 aging GO:0007568 9.79 BGLAP CALCA EPO
4 response to lipopolysaccharide GO:0032496 9.78 ACP5 CYP27B1 EPO TNFRSF11B
5 calcium ion transport GO:0006816 9.76 CASR CYP27B1 VDR
6 skeletal system development GO:0001501 9.71 BGLAP PTH TNFRSF11B VDR
7 embryo implantation GO:0007566 9.63 CALCA EPO
8 bone mineralization GO:0030282 9.62 BGLAP CYP27B1
9 response to testosterone GO:0033574 9.62 BGLAP EPO
10 vasodilation GO:0042311 9.61 CALCA CASR
11 bone resorption GO:0045453 9.6 ACP5 PTH
12 decidualization GO:0046697 9.59 CYP27B1 VDR
13 positive regulation of ossification GO:0045778 9.58 CALCA PTH
14 response to inorganic substance GO:0010035 9.57 BGLAP TNFRSF11B
15 positive regulation of keratinocyte differentiation GO:0045618 9.56 CYP27B1 VDR
16 cellular calcium ion homeostasis GO:0006874 9.56 CALCA CASR PTH VDR
17 response to magnesium ion GO:0032026 9.55 FGF23 TNFRSF11B
18 negative regulation of bone resorption GO:0045779 9.54 CALCA TNFRSF11B
19 regulation of bone mineralization GO:0030500 9.54 BGLAP CYP27B1 FGF23
20 vitamin D metabolic process GO:0042359 9.52 CYP27B1 FGF23
21 response to fibroblast growth factor GO:0071774 9.51 CASR PTH
22 response to vitamin D GO:0033280 9.5 BGLAP CYP27B1 PTH
23 negative regulation of calcium ion transport into cytosol GO:0010523 9.49 CALCA EPO
24 response to estrogen GO:0043627 9.46 BGLAP CYP27B1 EPO TNFRSF11B
25 vitamin D catabolic process GO:0042369 9.43 CYP27B1 FGF23
26 cellular response to vitamin D GO:0071305 9.13 BGLAP CASR FGF23
27 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 8.8 CYP27B1 FGF23 VDR

Molecular functions related to Secondary Hyperparathyroidism of Renal Origin according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 CALCA EPO PTH

Sources for Secondary Hyperparathyroidism of Renal Origin

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....